In high-risk ALL patients, several target fusions have been identified, which involve a distinct number of kinases (e.g., CSF1R, PDGFRB, ABL1, or ABL2) and exhibit an ALL Ph-like signature, thus suggesting a therapeutic approach should be used that is based on therapy with tyrosine kinase inhibitors, as demonstrated in the Ph+ ALL patients [163,165,166]. This evidence concerns the gene CSF1R and acute lymphoblastic leukemia.